Cargando…
Inhibitors of the Ras Superfamily G-proteins. Part B /
Targeted toward researchers in biochemistry, molecular and cell biology, pharmacology, and cancer, this is the second part of The Enzymes' volumes that discuss inhibitors of the Ras superfamily G-proteins. Key features: Contributions from leading authorities, Informs and updates on all the late...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Burlington :
Elsevier Science,
2014.
|
| Colección: | Enzymes ;
v. 34. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn863823787 | ||
| 003 | OCoLC | ||
| 005 | 20231117044931.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 131123s2014 vtu o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCQ |d TEF |d N$T |d OCLCF |d OHS |d OCLCQ |d DEBSZ |d OCLCQ |d DEBBG |d MEU |d OCLCQ |d D6H |d OTZ |d AU@ |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO | ||
| 019 | |a 1028553655 | ||
| 020 | |a 9780124202115 |q (electronic bk.) | ||
| 020 | |a 012420211X |q (electronic bk.) | ||
| 020 | |a 0124201466 | ||
| 020 | |a 9780124201460 | ||
| 020 | |z 9780124201460 | ||
| 035 | |a (OCoLC)863823787 |z (OCoLC)1028553655 | ||
| 050 | 4 | |a QP552.G16 | |
| 072 | 7 | |a SCI |x 007000 |2 bisacsh | |
| 082 | 0 | 4 | |a 572.6 |2 23 |
| 100 | 1 | |a Tamanoi, Fuyuhiko. | |
| 245 | 1 | 0 | |a Inhibitors of the Ras Superfamily G-proteins. |n Part B / |c Fuyuhiko Tamanoi, Channing J. Der. |
| 260 | |a Burlington : |b Elsevier Science, |c 2014. | ||
| 300 | |a 1 online resource (275 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 505 | 0 | |a Front Cover; Inhibitors of the Ras Superfamily G-proteins, Part B; Copyright; Contents; Preface; Chapter One: Discovery of Small-Molecule Ras Inhibitors that Display Antitumor Activity by Interfering with Ras. GTP-Effec ... ; 1. Introduction; 2. Discovery of Surface Pockets in Novel Crystal Structures of Ras. GTP; 3. Discovery of the Kobe0065-Family Compounds by In Silico Screening; 4. Inhibition of Ras Functions by the Kobe0065-Family Compounds; 4.1. Inhibition of Ras-Effector interaction; 4.2. Inhibition of proliferation of cultured cancer cells. | |
| 505 | 8 | |a 4.3. Inhibition of tumor growth in a xenograft model5. Structural Basis for Inhibition of Ras Functions by the Kobe0065-Family Compounds; 6. Specificity of the Kobe0065-Family Compounds Toward Various Small GTPases; 7. Discussion and Conclusion; Acknowledgments; References; Chapter Two: An Orthosteric Inhibitor of the RAS-SOS Interaction; 1. Introduction; 2. RAS Signaling in Normal Physiology and Malignancy; 3. Strategies for Targeting RAS Activity; 4. Inhibitor Design; 5. RAS Binding; 6. Cell Entry and Intracellular Effects; 7. Conclusions; References. | |
| 505 | 8 | |a Chapter Three: Conformation-Specific Inhibitors of Raf Kinases1. Introduction; 2. Kinase Conformations and Different Types of Kinase Inhibitors; 3. Representative Raf Inhibitors and Their Binding Modes; 4. Raf Kinase Dimerization and Activation; 5. Perspective; 6. Conclusion; Acknowledgments; References; Chapter Four: Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers; 1. Introduction; 2. Ras and the ERK MAPK Effector Signaling Network; 2.1. H-Ras, K-Ras4A/4B, and N-Ras; 2.2. A-Raf, B-Raf, and C-Raf/Raf-1; 2.3. MEK1 and MEK2; 2.4. ERK1 and ERK2. | |
| 505 | 8 | |a 3. Role of the ERK MAPK Cascade in Mutant RAS-Dependent Tumor Progression and Maintenance4. MEK1/2 Inhibitors; 4.1. Trametinib; 4.2. Selumetinib; 4.3. Pimasertib; 4.4. Cobimetinib; 4.5. PD0325901; 4.6. Refametinib; 4.7. AZD8330; 4.8. TAK-733; 4.9. MEK162; 4.10. RO5126766; 4.11. RO4987655; 4.12. E6201; 5. ERK1/2 Inhibitors; 5.1. SCH772984; 5.2. MK-8353/SCH900353; 5.3. BVD-523; 5.4. VTX11e; 5.5. AEZS-131/AEZS-134; 5.6. FR180204; 6. Issues and Questions; Acknowledgments; References; Chapter Five: Inhibiting the RAS-PI3K Pathway in Cancer Therapy; 1. Introduction; 2. The PI3K Pathway. | |
| 505 | 8 | |a 3. PI3K Inhibitors4. PI3K Pathway Inhibitors; 5. Inhibiting PI3K in Cancer; 6. Future Directions; References; Chapter Six: The RalGEF/Ral Pathway: Evaluating an Intervention Opportunity for Ras Cancers; 1. Introduction; 1.1. Oncogenic Ras signaling: Targeting troubles prompt alternative approaches; 1.2. RalGEF/Ral pathway overview; 1.2.1. RalGEFs; 1.2.2. Ral GTPases and their effectors; 1.2.3. RalGAPs; 2. RalGEF/Ral Signaling and Cancer: A Rationale for Pathway Inhibition; 2.1. Evidence from tumor cell models; 2.2. Evidence from genetically engineered mouse models. | |
| 500 | |a 2.3. Evidence from clinical correlates. | ||
| 520 | |a Targeted toward researchers in biochemistry, molecular and cell biology, pharmacology, and cancer, this is the second part of The Enzymes' volumes that discuss inhibitors of the Ras superfamily G-proteins. Key features: Contributions from leading authorities, Informs and updates on all the latest developments in the field. | ||
| 588 | 0 | |a Print version record. | |
| 546 | |a Text in English. | ||
| 650 | 0 | |a Ras proteins. | |
| 650 | 2 | |a ras Proteins |0 (DNLM)D018631 | |
| 650 | 6 | |a Prot�eines ras. |0 (CaQQLa)201-0247764 | |
| 650 | 7 | |a SCIENCE |x Life Sciences |x Biochemistry. |2 bisacsh | |
| 650 | 7 | |a Ras proteins |2 fast |0 (OCoLC)fst01090194 | |
| 700 | 1 | |a Der, Channing J. | |
| 776 | 0 | 8 | |i Print version: |a Tamanoi, Fuyuhiko. |t Inhibitors of the Ras Superfamily G-proteins, Part B. |d Burlington : Elsevier Science, �2014 |z 9780124201460 |
| 830 | 0 | |a Enzymes ; |v v. 34. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780124201460 |z Texto completo |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/bookseries/18746047/34 |z Texto completo |